Option chain shows key data for Emmaus Life Sciences's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Emmaus Life Sciences.

Emmaus Life Sciences (OTC:EMMA) Stock, Option Chain

Emmaus Life Sciences Inc is a biopharmaceutical company engaged in the discovery, development, and commercialization of new treatments and therapies predominantly for rare and orphan diseases. The company's commercial product is Endari, an oral pharmaceutical grade L-glutamine treatment indicated to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its products in the pipeline include Diverticulosis and Cell Sheet Engineering.

Penny,Stock,Investments,Taking,Off,Concept

Penny Stocks

Markets

EMMA

ProMIS Neurosciences And 2 Other Stocks Under $5 Executives Are Buying

Long Ideas

News

Insider Trades

Pre-Market Outlook

Trading Ideas

ETST

The Dow Jones index closed higher by around 0.1% on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Great Elm Group And 2 Other Stocks Under $2 Insiders Are Buying

AWRE

STRR

US crude oil futures traded sharply higher this morning on Friday. Investors, meanwhile, focused on some notable insider trades.

When insiders purchase or sell shares, it indicates their confidence or concern around the company&#39;s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.

Star Equity Holdings And 2 Other Stocks Under $2 Insiders Are Aggressively Buying

EMMAUS LIFE SCIENCES INC by Emmaus Life Sciences, Inc.

Emmaus Life Sciences Inc

<p>In the last three months, 13 analysts have published ratings on Texas Instruments (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXN#NASDAQ">TXN</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $217.69, a high estimate of $298.00, and a low estimate of $167.00. Experiencing a 1.05% decline, the current average is now lower than the previous average price target of $220.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732287660_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A comprehensive examination of how financial experts perceive Texas Instruments is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joe Quatrochi</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$215.00</td>
<td>-</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$215.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>William Stein</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$190.00</td>
<td>$198.00</td>
</tr>
<tr>
<td>C J Muse</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$200.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Blayne Curtis</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$200.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Mark Lipacis</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$298.00</td>
<td>$268.00</td>
</tr>
<tr>
<td>Joseph Moore</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$167.00</td>
<td>$154.00</td>
</tr>
<tr>
<td>Tristan Gerra</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$175.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Hans Mosesmann</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Cody Acree</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$230.00</td>
<td>$230.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$240.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>Hans Mosesmann</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$250.00</td>
<td>$250.00</td>
</tr>
<tr>
<td>C J Muse</td>
<td>Cantor Fitzgerald</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$200.00</td>
<td>$210.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Texas Instruments. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Texas Instruments compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Texas Instruments's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>For valuable insights into Texas Instruments's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TXN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Texas Instruments analyst ratings.</strong></a></p>
<h2>All You Need to Know About Texas Instruments</h2>
<p>Dallas-based Texas Instruments generates over 95% of its revenue from semiconductors and the remainder from its well-known calculators. Texas Instruments is the world's largest maker of analog chips, which are used to process real-world signals such as sound and power. Texas Instruments also has a leading market share position in processors and microcontrollers used in a wide variety of electronics applications.</p>
<h3>Understanding the Numbers: Texas Instruments's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> Texas Instruments's revenue growth over 3 months faced difficulties. As of 30 September, 2024, the company experienced a decline of approximately <strong>-8.41%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Texas Instruments's net margin excels beyond industry benchmarks, reaching <strong>32.64%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Texas Instruments's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>7.86%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Texas Instruments's ROA excels beyond industry benchmarks, reaching <strong>3.85%</strong>. This signifies efficient management of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>0.84</strong>, caution is advised due to increased financial risk.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

What 13 Analyst Ratings Have To Say About Texas Instruments

<p>High-rolling investors have positioned themselves bearish on CrowdStrike Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>), and it's important for retail traders to take note.<br />
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in CRWD often signals that someone has privileged information.</p>
<p>Today, Benzinga's options scanner spotted 9 options trades for CrowdStrike Holdings. This is not a typical pattern.</p>
<p>The sentiment among these major traders is split, with 22% bullish and 55% bearish. Among all the options we identified, there was one put, amounting to $61,500, and 8 calls, totaling $240,940.</p>
<h3>Predicted Price Range</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $80.0 to $370.0 for CrowdStrike Holdings over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of CrowdStrike Holdings stands at 932.67, with a total volume reaching 124.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in CrowdStrike Holdings, situated within the strike price corridor from $80.0 to $370.0, throughout the last 30 days.</p>
<h3>CrowdStrike Holdings Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732287660_0_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>CRWD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/13/24</td>
<td>$21.05</td>
<td>$19.3</td>
<td>$20.5</td>
<td>$365.00</td>
<td>$61.5K</td>
<td>7</td>
<td align="right">38</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$87.15</td>
<td>$84.7</td>
<td>$86.5</td>
<td>$280.00</td>
<td>$34.6K</td>
<td>967</td>
<td align="right">4</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/06/24</td>
<td>$26.3</td>
<td>$23.0</td>
<td>$23.0</td>
<td>$350.00</td>
<td>$34.5K</td>
<td>369</td>
<td align="right">0</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$21.4</td>
<td>$20.2</td>
<td>$20.84</td>
<td>$370.00</td>
<td>$31.2K</td>
<td>1.5K</td>
<td align="right">18</td>
</tr>
<tr>
<td>CRWD</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$30.05</td>
<td>$29.7</td>
<td>$29.7</td>
<td>$350.00</td>
<td>$29.7K</td>
<td>2.7K</td>
<td align="right">41</td>
</tr>
</tbody>
</table>
</p>
<h3>About CrowdStrike Holdings</h3>
<p>CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.</p>
<p>Having examined the options trading patterns of CrowdStrike Holdings, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Present Market Standing of CrowdStrike Holdings</h3>
<ul>
<li>Currently trading with a volume of 328,151, the CRWD's price is up by 1.61%, now at $363.32. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 4 days.</li>
</ul>
<h3>Professional Analyst Ratings for CrowdStrike Holdings</h3>
<p>A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $358.4.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Barclays persists with their Overweight rating on CrowdStrike Holdings, maintaining a target price of $372.<br />
&#x2A; In a cautious move, an analyst from CICC downgraded its rating to Market Perform, setting a price target of $295.<br />
&#x2A; An analyst from JMP Securities downgraded its action to Market Outperform with a price target of $400.<br />
&#x2A; An analyst from Cantor Fitzgerald persists with their Overweight rating on CrowdStrike Holdings, maintaining a target price of $370.<br />
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Overweight rating on CrowdStrike Holdings with a target price of $355. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for CrowdStrike Holdings, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

CRWD

Market Whales and Their Recent Bets on CRWD Options

<p>Financial giants have made a conspicuous bearish move on Coinbase Glb. Our analysis of options history for Coinbase Glb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) revealed 13 unusual trades.</p>
<p>Delving into the details, we found 30% of traders were bullish, while 61% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $199,775, and 9 were calls, valued at $1,065,267.</p>
<h3>Predicted Price Range</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $80.0 to $470.0 for Coinbase Glb over the last 3 months. </p>
<h3>Analyzing Volume &amp; Open Interest</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Coinbase Glb's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Coinbase Glb's substantial trades, within a strike price spectrum from $80.0 to $470.0 over the preceding 30 days.</p>
<h3>Coinbase Glb 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732287654_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>COIN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$13.7</td>
<td>$13.1</td>
<td>$13.31</td>
<td>$300.00</td>
<td>$266.0K</td>
<td>3.1K</td>
<td>864</td>
</tr>
<tr>
<td>COIN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/22/24</td>
<td>$215.4</td>
<td>$212.7</td>
<td>$215.4</td>
<td>$80.00</td>
<td>$193.8K</td>
<td>6</td>
<td>0</td>
</tr>
<tr>
<td>COIN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/29/24</td>
<td>$7.5</td>
<td>$7.0</td>
<td>$7.28</td>
<td>$320.00</td>
<td>$145.6K</td>
<td>1.9K</td>
<td>10.5K</td>
</tr>
<tr>
<td>COIN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>11/29/24</td>
<td>$86.05</td>
<td>$83.3</td>
<td>$83.74</td>
<td>$215.00</td>
<td>$125.6K</td>
<td>195</td>
<td>21</td>
</tr>
<tr>
<td>COIN</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/27/24</td>
<td>$60.0</td>
<td>$57.95</td>
<td>$59.7</td>
<td>$250.00</td>
<td>$119.4K</td>
<td>74</td>
<td>0</td>
</tr>
</tbody>
</table>
</p>
<h3>About Coinbase Glb</h3>
<p>Founded in 2012, Coinbase is the leading cryptocurrency exchange platform in the United States. The company intends to be the safe and regulation-compliant point of entry for retail investors and institutions into the cryptocurrency economy. Users can establish an account directly with the firm, instead of using an intermediary, and many choose to allow Coinbase to act as a custodian for their cryptocurrency, giving the company breadth beyond that of a traditional financial exchange. While the company still generates the majority of its revenue from transaction fees charged to its retail customers, Coinbase uses internal investment and acquisitions to expand into adjacent businesses, such as prime brokerage and data analytics.</p>
<p>Following our analysis of the options activities associated with Coinbase Glb, we pivot to a closer look at the company's own performance.</p>
<h3>Current Position of Coinbase Glb</h3>
<ul>
<li>With a volume of 1,995,834, the price of COIN is up 0.17% at $295.74. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 83 days.</li>
</ul>
<h3>What Analysts Are Saying About Coinbase Glb</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $239.6.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from B of A Securities continues to hold a Neutral rating for Coinbase Glb, targeting a price of $214.<br />
&#x2A; An analyst from Barclays has decided to maintain their Equal-Weight rating on Coinbase Glb, which currently sits at a price target of $204.<br />
&#x2A; Reflecting concerns, an analyst from Piper Sandler lowers its rating to Neutral with a new price target of $245.<br />
&#x2A; Consistent in their evaluation, an analyst from Needham keeps a Buy rating on Coinbase Glb with a target price of $290.<br />
&#x2A; An analyst from Monness, Crespi, Hardt downgraded its action to Buy with a price target of $245. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Coinbase Glb, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


COIN

Looking At Coinbase Glb's Recent Unusual Options Activity

<p>Throughout the last three months, 7 analysts have evaluated Insmed (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INSM#NASDAQ">INSM</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $89.71, a high estimate of $105.00, and a low estimate of $74.00. This upward trend is evident, with the current average reflecting a 5.54% increase from the previous average price target of $85.00.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732287652_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A clear picture of Insmed's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$83.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Nicole Germino</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$105.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Nicole Germino</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Jason Zemansky</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$86.00</td>
<td>$84.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$74.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Andrew Fein</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$90.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Insmed. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Insmed compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Insmed's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Capture valuable insights into Insmed's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/INSM/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Insmed analyst ratings.</strong></a></p>
<h2>About Insmed</h2>
<p>Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.</p>
<h3>A Deep Dive into Insmed's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Insmed's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>18.15%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Insmed's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>-236.04%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-84.45%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Insmed's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-11.42%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>2.07</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


INSM

Demystifying Insmed: Insights From 7 Analyst Reviews

<p>Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) is gearing up to announce its quarterly earnings on Monday, 2024-11-25. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Enanta Pharma will report an <strong>earnings per share</strong> (EPS) of $-1.16.</p>
<p>The announcement from Enanta Pharma is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Historical Earnings Performance</h3>
<p>In the previous earnings release, the company beat EPS by $0.38, leading to a 1.17% increase in the share price the following trading session.</p>
<p>Here's a look at Enanta Pharma's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-1.45</td>
<td>-1.33</td>
<td>-1.19</td>
<td>-2</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-1.07</td>
<td>-1.47</td>
<td>-1.58</td>
<td>-1.33</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-10.0%</td>
<td>1.0%</td>
<td>12.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732287651_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Enanta Pharma were trading at $9.31 as of November 21. Over the last 52-week period, shares are down 1.98%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. </p>
<h3>Analyst Views on Enanta Pharma</h3>
<p>For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Enanta Pharma.</p>
<p>A total of 3 analyst ratings have been received for Enanta Pharma, with the consensus rating being Outperform. The average one-year price target stands at $23.67, suggesting a potential 154.24% upside.</p>
<h3>Comparing Ratings with Peers</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of  and Macrogenics, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<h3>Overview of Peer Analysis</h3>
<p>The peer analysis summary presents essential metrics for  and Macrogenics, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Macrogenics</td>
<td>Neutral</td>
<td>964.81%</td>
<td>$108.84M</td>
<td>63.31%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Enanta Pharma ranks in the middle among its peers for Consensus rating. It is at the top for Revenue Growth, indicating strong performance in this area. Enanta Pharma also leads in Gross Profit, showcasing efficient cost management. However, it falls behind in Return on Equity compared to its peers.</p>
<h3>Delving into Enanta Pharma's Background</h3>
<p>Enanta Pharmaceuticals Inc is an American biotechnology company focused on the research and development of molecule drugs to cure viral infections and liver diseases. The targeted diseases are hepatitis C, hepatitis B, nonalcoholic steatohepatitis, and the respiratory syncytial virus. The novelty of company research is a specific direct-acting antiviral inhibitor against the hepatitis C virus. The company's inhibitors have been developed in collaboration with AbbVie. AbbVie markets the protease inhibitor, paritaprevir, while other inhibitors are in the pipeline.</p>
<h3>Financial Milestones: Enanta Pharma's Journey</h3>
<p><strong>Market Capitalization Highlights:</strong> Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, Enanta Pharma faced challenges, resulting in a decline of approximately <strong>-4.88%</strong> in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Enanta Pharma's net margin excels beyond industry benchmarks, reaching <strong>-126.08%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Enanta Pharma's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-14.38%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-5.58%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Enanta Pharma's debt-to-equity ratio surpasses industry norms, standing at <strong>0.34</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<p><a href="https://www.benzinga.com/quote/ENTA/earnings"><strong>To track all earnings releases for Enanta Pharma visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings

ENTA

Enanta Pharma's Earnings Outlook

Macro Economic Events

Econ #s

Economics

Michigan Consumer Expectations For November 76.9 Vs. 78.5 Est.; 78.5 Prior

<p>Codexis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXS#NASDAQ">CDXS</a>) underwent analysis by 4 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $11.0, with a high estimate of $11.00 and a low estimate of $11.00. This current average is unchanged from the previous average price target. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732287644_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The standing of Codexis among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$11.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Codexis. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Codexis compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Codexis's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CDXS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Codexis analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Codexis: A Closer Look</h2>
<p>Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.</p>
<h3>Financial Insights: Codexis</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Codexis's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>38.33%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of <strong>-160.84%,</strong> the company showcases strong profitability and effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Codexis's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-30.61%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Codexis's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-14.73%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.57</strong>, Codexis adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


CDXS

Deep Dive Into Codexis Stock: Analyst Perspectives (4 Ratings)

<p>In the ever-changing and fiercely competitive business landscape, conducting thorough company analysis is crucial for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating <b>Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)</b> and its primary competitors in the Broadline Retail industry. By closely examining key financial metrics, market position, and growth prospects, our aim is to provide valuable insights for investors and shed light on company's performance within the industry.</p>
<h3>Amazon.com Background</h3>
<p>Amazon is the leading online retailer and marketplace for third party sellers. Retail related revenue represents approximately 75% of total, followed by Amazon Web Services' cloud computing, storage, database, and other offerings (15%), advertising services (5% to 10%), and other the remainder. International segments constitute 25% to 30% of Amazon's non-AWS sales, led by Germany, the United Kingdom, and Japan.</p>
<table>
<thead>
<tr>
<th><strong>Company</strong></th>
<th><strong>P/E</strong></th>
<th><strong>P/B</strong></th>
<th><strong>P/S</strong></th>
<th><strong>ROE</strong></th>
<th><strong>EBITDA (in billions)</strong></th>
<th><strong>Gross Profit (in billions)</strong></th>
<th><strong>Revenue Growth</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Amazon.com Inc</td>
<td>42.39</td>
<td>8.05</td>
<td>3.42</td>
<td>6.19%</td>
<td>$32.08</td>
<td>$31.0</td>
<td>11.04%</td>
</tr>
<tr>
<td>Alibaba Group Holding Ltd</td>
<td>17.62</td>
<td>1.55</td>
<td>1.60</td>
<td>4.64%</td>
<td>$54.02</td>
<td>$92.47</td>
<td>5.21%</td>
</tr>
<tr>
<td>PDD Holdings Inc</td>
<td>11.22</td>
<td>4.12</td>
<td>3.24</td>
<td>13.54%</td>
<td>$37.97</td>
<td>$63.36</td>
<td>85.65%</td>
</tr>
<tr>
<td>MercadoLibre Inc</td>
<td>69.82</td>
<td>24.93</td>
<td>5.46</td>
<td>10.37%</td>
<td>$0.72</td>
<td>$2.44</td>
<td>35.27%</td>
</tr>
<tr>
<td>JD.com Inc</td>
<td>11.38</td>
<td>1.63</td>
<td>0.36</td>
<td>5.22%</td>
<td>$15.92</td>
<td>$45.04</td>
<td>5.12%</td>
</tr>
<tr>
<td>Coupang Inc</td>
<td>42.19</td>
<td>10.31</td>
<td>1.49</td>
<td>1.74%</td>
<td>$0.28</td>
<td>$2.27</td>
<td>27.2%</td>
</tr>
<tr>
<td>eBay Inc</td>
<td>15.47</td>
<td>5.43</td>
<td>3.05</td>
<td>11.59%</td>
<td>$0.95</td>
<td>$1.85</td>
<td>3.04%</td>
</tr>
<tr>
<td>Vipshop Holdings Ltd</td>
<td>6.43</td>
<td>1.33</td>
<td>0.48</td>
<td>2.76%</td>
<td>$1.47</td>
<td>$4.96</td>
<td>-9.18%</td>
</tr>
<tr>
<td>Dillard's Inc</td>
<td>11.19</td>
<td>3.51</td>
<td>1.05</td>
<td>6.37%</td>
<td>$0.15</td>
<td>$0.58</td>
<td>-4.19%</td>
</tr>
<tr>
<td>Ollie's Bargain Outlet Holdings Inc</td>
<td>27.67</td>
<td>3.50</td>
<td>2.53</td>
<td>3.14%</td>
<td>$0.08</td>
<td>$0.22</td>
<td>12.41%</td>
</tr>
<tr>
<td>MINISO Group Holding Ltd</td>
<td>17.10</td>
<td>3.97</td>
<td>2.79</td>
<td>6.26%</td>
<td>$0.79</td>
<td>$1.77</td>
<td>24.08%</td>
</tr>
<tr>
<td>Macy's Inc</td>
<td>23.18</td>
<td>0.97</td>
<td>0.18</td>
<td>3.53%</td>
<td>$0.44</td>
<td>$2.16</td>
<td>-3.48%</td>
</tr>
<tr>
<td>Nordstrom Inc</td>
<td>12.93</td>
<td>3.87</td>
<td>0.25</td>
<td>13.68%</td>
<td>$0.4</td>
<td>$1.49</td>
<td>3.23%</td>
</tr>
<tr>
<td>Kohl's Corp</td>
<td>6.43</td>
<td>0.48</td>
<td>0.11</td>
<td>1.73%</td>
<td>$0.35</td>
<td>$1.6</td>
<td>-4.18%</td>
</tr>
<tr>
<td>Savers Value Village Inc</td>
<td>18.83</td>
<td>3.20</td>
<td>0.95</td>
<td>5.09%</td>
<td>$0.07</td>
<td>$0.22</td>
<td>0.53%</td>
</tr>
<tr>
<td>Groupon Inc</td>
<td>13.33</td>
<td>9.15</td>
<td>0.68</td>
<td>34.72%</td>
<td>$0.03</td>
<td>$0.1</td>
<td>-9.48%</td>
</tr>
<tr>
<td><strong>Average</strong></td>
<td><strong>20.32</strong></td>
<td><strong>5.2</strong></td>
<td><strong>1.61</strong></td>
<td><strong>8.29%</strong></td>
<td><strong>$7.58</strong></td>
<td><strong>$14.7</strong></td>
<td><strong>11.42%</strong></td>
</tr>
</tbody>
</table>
<style>
        table {
            width: 100%;
            border-collapse: collapse;
            font-family: Arial, sans-serif;
            font-size: 14px;
        }

        th, td {
            padding: 8px;
            text-align: left;
        }

        th {
            background-color: #293a5a;
            color: #fff;
            text-align: left;
        }

        tr:nth-child(even) {
            background-color: #f2f4f8;
        }

        tr:hover {
            background-color: #e1e4ea;
        }

        td:nth-child(3), td:nth-child(5) {
            text-align: left;
        }

        .dividend-amount {
            font-weight: bold;
            color: #0d6efd;
        }

        .dividend-frequency {
            font-size: 12px;
            color: #6c757d;
        }
    </style><p>By closely examining Amazon.com, we can identify the following trends: </p>
<ul>
<li>
<p>Notably, the current Price to Earnings ratio for this stock, <b>42.39</b>, is <b>2.09x</b> above the industry norm, reflecting a higher valuation relative to the industry.</p>
</li>
<li>
<p>With a Price to Book ratio of <b>8.05</b>, which is <b>1.55x</b> the industry average, Amazon.com might be considered overvalued in terms of its book value, as it is trading at a higher multiple compared to its industry peers.</p>
</li>
<li>
<p>The Price to Sales ratio of <b>3.42</b>, which is <b>2.12x</b> the industry average, suggests the stock could potentially be overvalued in relation to its sales performance compared to its peers.</p>
</li>
<li>
<p>The company has a lower Return on Equity (ROE) of <b>6.19%</b>, which is <b>2.1%</b> below the industry average. This indicates potential inefficiency in utilizing equity to generate profits, which could be attributed to various factors.</p>
</li>
<li>
<p>The Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of <b>$32.08 Billion</b> is <b>4.23x</b> above the industry average, highlighting stronger profitability and robust cash flow generation.</p>
</li>
<li>
<p>The company has higher gross profit of <b>$31.0 Billion</b>, which indicates <b>2.11x</b> above the industry average, indicating stronger profitability and higher earnings from its core operations.</p>
</li>
<li>
<p>The company's revenue growth of <b>11.04%</b> is significantly lower compared to the industry average of <b>11.42%</b>. This indicates a potential fall in the company's sales performance.</p>
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732287643_0.png" alt="debt to equity" /></p>
<p>The debt-to-equity (D/E) ratio is an important measure to assess the financial structure and risk profile of a company.</p>
<p>Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.</p>
<p>When evaluating Amazon.com alongside its top 4 peers in terms of the Debt-to-Equity ratio, the following insights arise:</p>
<ul>
<li>
<p>Compared to its top 4 peers, Amazon.com has a stronger financial position indicated by its lower debt-to-equity ratio of <b>0.52</b>.</p>
</li>
<li>
<p>This suggests that the company relies less on debt financing and has a more favorable balance between debt and equity, which can be seen as a positive attribute by investors.</p>
</li>
</ul>
<h3>Key Takeaways</h3>
<p>For Amazon.com, the PE, PB, and PS ratios are all high compared to its peers in the Broadline Retail industry, indicating overvaluation. The low ROE suggests lower profitability relative to its high EBITDA and gross profit margins. Additionally, the low revenue growth implies a slower expansion rate compared to industry peers.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


AMZN

Investigating Amazon.com's Standing In Broadline Retail Industry Compared To Competitors

<p>Bath &amp; Body Works (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBWI#NYSE">BBWI</a>) is gearing up to announce its quarterly earnings on Monday, 2024-11-25. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Bath &amp; Body Works will report an <strong>earnings per share</strong> (EPS) of $0.47.</p>
<p>Anticipation surrounds Bath &amp; Body Works's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.</p>
<p>New investors should understand that while earnings performance is important, market reactions are often driven by guidance.</p>
<h3>Past Earnings Performance</h3>
<p>During the last quarter, the company reported an EPS beat by $0.01, leading to a 4.0% drop in the share price on the subsequent day.</p>
<p>Here's a look at Bath &amp; Body Works's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>0.36</td>
<td>0.32</td>
<td>1.87</td>
<td>0.35</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>0.37</td>
<td>0.38</td>
<td>2.06</td>
<td>0.48</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>-4.0%</td>
<td>5.0%</td>
<td>-0.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732287638_0.png" alt="eps graph" /></p>
<h3>Stock Performance</h3>
<p>Shares of Bath &amp; Body Works were trading at $30.55 as of November 21. Over the last 52-week period, shares are up 2.21%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<p><a href="https://www.benzinga.com/quote/BBWI/earnings"><strong>To track all earnings releases for Bath &amp; Body Works visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


BBWI

Earnings Preview: Bath & Body Works

<p>Stifel  analyst Brad Reback   maintains Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) with a Buy and lowers the price target from $795 to $725.</p>


Price Target

INTU

Stifel Maintains Buy on Intuit, Lowers Price Target to $725

<p>Across the recent three months, 13 analysts have shared their insights on Tenet Healthcare (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/THC#NYSE">THC</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Tenet Healthcare and provided 12-month price targets. The average target is $189.54, accompanied by a high estimate of $217.00 and a low estimate of $168.00. Marking an increase of 6.58%, the current average surpasses the previous average price target of $177.83. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732287634_0.png" alt="price target chart" /></p>
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
<p>A clear picture of Tenet Healthcare's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Ransom</td>
<td>Raymond James</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$195.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$190.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$205.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$177.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Jamie Perse</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$196.00</td>
<td>$173.00</td>
</tr>
<tr>
<td>Ben Hendrix</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$183.00</td>
<td>$174.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>A.J. Rice</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$217.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Stephen Baxter</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$195.00</td>
<td>$175.00</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$180.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Matthew Gillmor</td>
<td>Keybanc</td>
<td>Announces</td>
<td>Overweight</td>
<td>$200.00</td>
<td>-</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$168.00</td>
<td>$168.00</td>
</tr>
<tr>
<td>Sarah James</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$168.00</td>
<td>$168.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Tenet Healthcare. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Tenet Healthcare compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Tenet Healthcare's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Capture valuable insights into Tenet Healthcare's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/THC/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Tenet Healthcare analyst ratings.</strong></a></p>
<h2>Delving into Tenet Healthcare's Background</h2>
<p>Tenet Healthcare is a Dallas-based healthcare services organization. It operates a collection of hospitals (about 50 as of July 2024) and over 500 ambulatory surgery centers and other outpatient facilities across the U.S., primarily in the South. Through its Conifer segment, Tenet also provides revenue cycle management solutions.</p>
<h3>Key Indicators: Tenet Healthcare's Financial Health</h3>
<p><strong>Market Capitalization:</strong> Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Tenet Healthcare's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>1.11%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Tenet Healthcare's net margin excels beyond industry benchmarks, reaching <strong>9.22%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Tenet Healthcare's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>12.92%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Tenet Healthcare's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.61%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> Tenet Healthcare's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>3.36</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Demystifying Tenet Healthcare: Insights From 13 Analyst Reviews

<p>In the ever-changing and fiercely competitive business landscape, conducting thorough company analysis is crucial for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating <b>Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>)</b> and its primary competitors in the Interactive Media &amp; Services industry. By closely examining key financial metrics, market position, and growth prospects, our aim is to provide valuable insights for investors and shed light on company's performance within the industry.</p>
<h3>Meta Platforms Background</h3>
<p>Meta is the largest social media company in the world, boasting close to 4 billion monthly active users worldwide. The firm's "Family of Apps," its core business, consists of Facebook, Instagram, Messenger, and WhatsApp. End users can leverage these applications for a variety of different purposes, from keeping in touch with friends to following celebrities and running digital businesses for free. Meta packages customer data, gleaned from its application ecosystem and sells ads to digital advertisers. While the firm has been investing heavily in its Reality Labs business, it remains a very small part of Meta's overall sales.</p>
<table>
<thead>
<tr>
<th><strong>Company</strong></th>
<th><strong>P/E</strong></th>
<th><strong>P/B</strong></th>
<th><strong>P/S</strong></th>
<th><strong>ROE</strong></th>
<th><strong>EBITDA (in billions)</strong></th>
<th><strong>Gross Profit (in billions)</strong></th>
<th><strong>Revenue Growth</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Meta Platforms Inc</td>
<td>26.57</td>
<td>8.64</td>
<td>9.45</td>
<td>9.77%</td>
<td>$22.06</td>
<td>$33.21</td>
<td>18.87%</td>
</tr>
<tr>
<td>Alphabet Inc</td>
<td>22.23</td>
<td>6.53</td>
<td>6.17</td>
<td>8.55%</td>
<td>$35.74</td>
<td>$51.79</td>
<td>15.09%</td>
</tr>
<tr>
<td>Baidu Inc</td>
<td>10.76</td>
<td>0.80</td>
<td>1.55</td>
<td>2.19%</td>
<td>$7.46</td>
<td>$17.53</td>
<td>-0.37%</td>
</tr>
<tr>
<td>Pinterest Inc</td>
<td>91.59</td>
<td>6.84</td>
<td>5.86</td>
<td>1.0%</td>
<td>$-0.0</td>
<td>$0.71</td>
<td>17.71%</td>
</tr>
<tr>
<td>Kanzhun Ltd</td>
<td>29.81</td>
<td>2.81</td>
<td>6.25</td>
<td>2.92%</td>
<td>$0.36</td>
<td>$1.6</td>
<td>28.85%</td>
</tr>
<tr>
<td>ZoomInfo Technologies Inc</td>
<td>345.67</td>
<td>2.13</td>
<td>3.17</td>
<td>1.35%</td>
<td>$0.07</td>
<td>$0.26</td>
<td>-3.25%</td>
</tr>
<tr>
<td>Ziff Davis Inc</td>
<td>42.70</td>
<td>1.40</td>
<td>1.88</td>
<td>-2.68%</td>
<td>$0.02</td>
<td>$0.3</td>
<td>3.69%</td>
</tr>
<tr>
<td>Yelp Inc</td>
<td>21.70</td>
<td>3.17</td>
<td>1.85</td>
<td>5.21%</td>
<td>$0.06</td>
<td>$0.33</td>
<td>4.41%</td>
</tr>
<tr>
<td>Weibo Corp</td>
<td>6.14</td>
<td>0.61</td>
<td>1.33</td>
<td>3.78%</td>
<td>$0.14</td>
<td>$0.37</td>
<td>5.05%</td>
</tr>
<tr>
<td>JOYY Inc</td>
<td>9.03</td>
<td>0.40</td>
<td>1.06</td>
<td>1.0%</td>
<td>$0.05</td>
<td>$0.2</td>
<td>3.25%</td>
</tr>
<tr>
<td>Tripadvisor Inc</td>
<td>51.73</td>
<td>1.99</td>
<td>1.10</td>
<td>4.33%</td>
<td>$0.1</td>
<td>$0.48</td>
<td>-0.19%</td>
</tr>
<tr>
<td>Hello Group Inc</td>
<td>6.64</td>
<td>0.75</td>
<td>0.82</td>
<td>3.57%</td>
<td>$0.54</td>
<td>$1.1</td>
<td>-14.22%</td>
</tr>
<tr>
<td><strong>Average</strong></td>
<td><strong>58.0</strong></td>
<td><strong>2.49</strong></td>
<td><strong>2.82</strong></td>
<td><strong>2.84%</strong></td>
<td><strong>$4.05</strong></td>
<td><strong>$6.79</strong></td>
<td><strong>5.46%</strong></td>
</tr>
</tbody>
</table>
<style>
        table {
            width: 100%;
            border-collapse: collapse;
            font-family: Arial, sans-serif;
            font-size: 14px;
        }

        th, td {
            padding: 8px;
            text-align: left;
        }

        th {
            background-color: #293a5a;
            color: #fff;
            text-align: left;
        }

        tr:nth-child(even) {
            background-color: #f2f4f8;
        }

        tr:hover {
            background-color: #e1e4ea;
        }

        td:nth-child(3), td:nth-child(5) {
            text-align: left;
        }

        .dividend-amount {
            font-weight: bold;
            color: #0d6efd;
        }

        .dividend-frequency {
            font-size: 12px;
            color: #6c757d;
        }
    </style><p>By thoroughly analyzing Meta Platforms, we can discern the following trends: </p>
<ul>
<li>
<p>At <b>26.57</b>, the stock's Price to Earnings ratio is <b>0.46x</b> less than the industry average, suggesting favorable growth potential.</p>
</li>
<li>
<p>It could be trading at a premium in relation to its book value, as indicated by its Price to Book ratio of <b>8.64</b> which exceeds the industry average by <b>3.47x</b>.</p>
</li>
<li>
<p>With a relatively high Price to Sales ratio of <b>9.45</b>, which is <b>3.35x</b> the industry average, the stock might be considered overvalued based on sales performance.</p>
</li>
<li>
<p>The company has a higher Return on Equity (ROE) of <b>9.77%</b>, which is <b>6.93%</b> above the industry average. This suggests efficient use of equity to generate profits and demonstrates profitability and growth potential.</p>
</li>
<li>
<p>The company exhibits higher Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of <b>$22.06 Billion</b>, which is <b>5.45x</b> above the industry average, implying stronger profitability and robust cash flow generation.</p>
</li>
<li>
<p>The company has higher gross profit of <b>$33.21 Billion</b>, which indicates <b>4.89x</b> above the industry average, indicating stronger profitability and higher earnings from its core operations.</p>
</li>
<li>
<p>With a revenue growth of <b>18.87%</b>, which surpasses the industry average of <b>5.46%</b>, the company is demonstrating robust sales expansion and gaining market share.</p>
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732287634_0_0.png" alt="debt to equity" /></p>
<p>The debt-to-equity (D/E) ratio is an important measure to assess the financial structure and risk profile of a company.</p>
<p>Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.</p>
<p>By evaluating Meta Platforms against its top 4 peers in terms of the Debt-to-Equity ratio, the following observations arise:</p>
<ul>
<li>
<p>Meta Platforms demonstrates a stronger financial position compared to its top 4 peers in the sector.</p>
</li>
<li>
<p>With a lower debt-to-equity ratio of <b>0.3</b>, the company relies less on debt financing and maintains a healthier balance between debt and equity, which can be viewed positively by investors.</p>
</li>
</ul>
<h3>Key Takeaways</h3>
<p>For Meta Platforms, the PE ratio is low compared to peers, indicating potential undervaluation. The high PB and PS ratios suggest the market values the company's assets and sales highly. In terms of ROE, EBITDA, gross profit, and revenue growth, Meta Platforms outperforms its industry peers, reflecting strong financial performance and growth potential.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Competitor Analysis: Evaluating Meta Platforms And Competitors In Interactive Media &amp; Services Industry

Michigan 5-Year Inflation Expectations For November 3.2% Vs 3.1% Est.; 3.1% Prior

<p>In today's rapidly evolving and fiercely competitive business landscape, it is crucial for investors and industry analysts to conduct comprehensive company evaluations. In this article, we will undertake an in-depth industry comparison, assessing <b>Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>)</b> alongside its primary competitors in the Technology Hardware, Storage &amp; Peripherals industry. By meticulously examining crucial financial indicators, market positioning, and growth potential, we aim to provide valuable insights to investors and shed light on company's performance within the industry.</p>
<h3>Apple Background</h3>
<p>Apple is among the largest companies in the world, with a broad portfolio of hardware and software products targeted at consumers and businesses. Apple's iPhone makes up a majority of the firm sales, and Apple's other products like Mac, iPad, and Watch are designed around the iPhone as the focal point of an expansive software ecosystem. Apple has progressively worked to add new applications, like streaming video, subscription bundles, and augmented reality. The firm designs its own software and semiconductors while working with subcontractors like Foxconn and TSMC to build its products and chips. Slightly less than half of Apple's sales come directly through its flagship stores, with a majority of sales coming indirectly through partnerships and distribution.</p>
<table>
<thead>
<tr>
<th><strong>Company</strong></th>
<th><strong>P/E</strong></th>
<th><strong>P/B</strong></th>
<th><strong>P/S</strong></th>
<th><strong>ROE</strong></th>
<th><strong>EBITDA (in billions)</strong></th>
<th><strong>Gross Profit (in billions)</strong></th>
<th><strong>Revenue Growth</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Apple Inc</td>
<td>37.59</td>
<td>60.65</td>
<td>9</td>
<td>23.83%</td>
<td>$32.5</td>
<td>$43.88</td>
<td>6.07%</td>
</tr>
<tr>
<td>Hewlett Packard Enterprise Co</td>
<td>15.42</td>
<td>1.28</td>
<td>0.99</td>
<td>2.34%</td>
<td>$1.23</td>
<td>$2.44</td>
<td>10.11%</td>
</tr>
<tr>
<td>NetApp Inc</td>
<td>24.79</td>
<td>27.92</td>
<td>4.21</td>
<td>23.9%</td>
<td>$0.38</td>
<td>$1.1</td>
<td>7.61%</td>
</tr>
<tr>
<td>Western Digital Corp</td>
<td>72.40</td>
<td>1.96</td>
<td>1.54</td>
<td>4.28%</td>
<td>$0.86</td>
<td>$1.55</td>
<td>48.91%</td>
</tr>
<tr>
<td>Super Micro Computer Inc</td>
<td>14.78</td>
<td>3.18</td>
<td>1.20</td>
<td>6.68%</td>
<td>$0.4</td>
<td>$0.6</td>
<td>37.87%</td>
</tr>
<tr>
<td>Pure Storage Inc</td>
<td>119.37</td>
<td>11.63</td>
<td>5.99</td>
<td>2.52%</td>
<td>$0.08</td>
<td>$0.54</td>
<td>10.91%</td>
</tr>
<tr>
<td>Eastman Kodak Co</td>
<td>7.39</td>
<td>0.42</td>
<td>0.45</td>
<td>1.34%</td>
<td>$0.04</td>
<td>$0.04</td>
<td>-2.97%</td>
</tr>
<tr>
<td>Turtle Beach Corp</td>
<td>48.77</td>
<td>2.98</td>
<td>0.90</td>
<td>3.3%</td>
<td>$0.01</td>
<td>$0.03</td>
<td>59.51%</td>
</tr>
<tr>
<td>Immersion Corp</td>
<td>4.82</td>
<td>1.21</td>
<td>1.72</td>
<td>13.41%</td>
<td>$0.03</td>
<td>$0.06</td>
<td>1323.8%</td>
</tr>
<tr>
<td>AstroNova Inc</td>
<td>17.86</td>
<td>1.23</td>
<td>0.76</td>
<td>-0.34%</td>
<td>$0.0</td>
<td>$0.01</td>
<td>14.12%</td>
</tr>
<tr>
<td><strong>Average</strong></td>
<td><strong>36.18</strong></td>
<td><strong>5.76</strong></td>
<td><strong>1.97</strong></td>
<td><strong>6.38%</strong></td>
<td><strong>$0.34</strong></td>
<td><strong>$0.71</strong></td>
<td><strong>167.76%</strong></td>
</tr>
</tbody>
</table>
<style>
        table {
            width: 100%;
            border-collapse: collapse;
            font-family: Arial, sans-serif;
            font-size: 14px;
        }

        th, td {
            padding: 8px;
            text-align: left;
        }

        th {
            background-color: #293a5a;
            color: #fff;
            text-align: left;
        }

        tr:nth-child(even) {
            background-color: #f2f4f8;
        }

        tr:hover {
            background-color: #e1e4ea;
        }

        td:nth-child(3), td:nth-child(5) {
            text-align: left;
        }

        .dividend-amount {
            font-weight: bold;
            color: #0d6efd;
        }

        .dividend-frequency {
            font-size: 12px;
            color: #6c757d;
        }
    </style><p>By closely studying Apple, we can observe the following trends: </p>
<ul>
<li>
<p>At <b>37.59</b>, the stock's Price to Earnings ratio significantly exceeds the industry average by <b>1.04x</b>, suggesting a premium valuation relative to industry peers.</p>
</li>
<li>
<p>It could be trading at a premium in relation to its book value, as indicated by its Price to Book ratio of <b>60.65</b> which exceeds the industry average by <b>10.53x</b>.</p>
</li>
<li>
<p>The stock's relatively high Price to Sales ratio of <b>9.0</b>, surpassing the industry average by <b>4.57x</b>, may indicate an aspect of overvaluation in terms of sales performance.</p>
</li>
<li>
<p>The Return on Equity (ROE) of <b>23.83%</b> is <b>17.45%</b> above the industry average, highlighting efficient use of equity to generate profits.</p>
</li>
<li>
<p>The company exhibits higher Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of <b>$32.5 Billion</b>, which is <b>95.59x</b> above the industry average, implying stronger profitability and robust cash flow generation.</p>
</li>
<li>
<p>The company has higher gross profit of <b>$43.88 Billion</b>, which indicates <b>61.8x</b> above the industry average, indicating stronger profitability and higher earnings from its core operations.</p>
</li>
<li>
<p>The company's revenue growth of <b>6.07%</b> is significantly below the industry average of <b>167.76%</b>. This suggests a potential struggle in generating increased sales volume.</p>
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732287626_0.png" alt="debt to equity" /></p>
<p>The debt-to-equity (D/E) ratio is an important measure to assess the financial structure and risk profile of a company.</p>
<p>Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.</p>
<p>By analyzing Apple in relation to its top 4 peers based on the Debt-to-Equity ratio, the following insights can be derived:</p>
<ul>
<li>
<p>Compared to its top 4 peers, Apple has a moderate debt-to-equity ratio of <b>1.87</b>, indicating a balanced financial structure.</p>
</li>
<li>
<p>This suggests that the company maintains a reasonable level of debt while also leveraging equity financing.</p>
</li>
</ul>
<h3>Key Takeaways</h3>
<p>For Apple in the Technology Hardware, Storage &amp; Peripherals industry, the PE, PB, and PS ratios are all high compared to peers, indicating a potentially overvalued stock. On the other hand, Apple's high ROE, EBITDA, and gross profit suggest strong profitability and operational efficiency. However, the low revenue growth rate may be a concern when compared to industry peers.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


AAPL

Insights Into Apple's Performance Versus Peers In Technology Hardware, Storage &amp; Peripherals Sector

<p>Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENT#NASDAQ">CENT</a>) is gearing up to announce its quarterly earnings on Monday, 2024-11-25. Here's a quick overview of what investors should know before the release.</p>
<p>Analysts are estimating that Central Garden &amp; Pet will report an <strong>earnings per share</strong> (EPS) of $-0.20.</p>
<p>The announcement from Central Garden &amp; Pet is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.</p>
<p>It's worth noting for new investors that guidance can be a key determinant of stock price movements.</p>
<h3>Past Earnings Performance</h3>
<p>The company's EPS beat by $0.11 in the last quarter, leading to a 5.84% increase in the share price on the following day.</p>
<p>Here's a look at Central Garden &amp; Pet's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>1.21</td>
<td>0.80</td>
<td>-0.14</td>
<td>0.06</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>1.32</td>
<td>0.99</td>
<td>0.01</td>
<td>0.08</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>6.0%</td>
<td>11.0%</td>
<td>6.0%</td>
<td>-10.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732287624_0.png" alt="eps graph" /></p>
<h3>Performance of Central Garden &amp; Pet Shares</h3>
<p>Shares of Central Garden &amp; Pet were trading at $38.36 as of November 21. Over the last 52-week period, shares are up 21.81%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analyst Views on Central Garden &amp; Pet</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Central Garden &amp; Pet.</p>
<p>A total of 2 analyst ratings have been received for Central Garden &amp; Pet, with the consensus rating being Buy. The average one-year price target stands at $44.0, suggesting a potential 14.7% upside.</p>
<h3>Comparing Ratings with Competitors</h3>
<p>This comparison focuses on the analyst ratings and average 1-year price targets of Spectrum Brands Holdings, Energizer Hldgs and WD-40, three major players in the industry, shedding light on their relative performance expectations and market positioning.</p>
<ul>
<li>As per analysts' assessments, Spectrum Brands Holdings is favoring an Neutral trajectory, with an average 1-year price target of $94.0, suggesting a potential 145.05% upside.</li>
<li>For Energizer Hldgs, analysts project an Neutral trajectory, with an average 1-year price target of $37.25, indicating a potential 2.89% downside.</li>
<li>WD-40 is maintaining an Buy status according to analysts, with an average 1-year price target of $308.0, indicating a potential 702.92% upside.</li>
</ul>
<h3>Peers Comparative Analysis Summary</h3>
<p>The peer analysis summary outlines pivotal metrics for Spectrum Brands Holdings, Energizer Hldgs and WD-40, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central Garden &amp; Pet</td>
<td>Buy</td>
<td>-2.63%</td>
<td>$317.06M</td>
<td>5.14%</td>
</tr>
<tr>
<td>Spectrum Brands Holdings</td>
<td>Neutral</td>
<td>4.46%</td>
<td>$288.10M</td>
<td>1.35%</td>
</tr>
<tr>
<td>Energizer Hldgs</td>
<td>Neutral</td>
<td>-0.67%</td>
<td>$306.80M</td>
<td>36.73%</td>
</tr>
<tr>
<td>WD-40</td>
<td>Buy</td>
<td>11.06%</td>
<td>$84.34M</td>
<td>7.39%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Central Garden &amp; Pet ranks at the top for Revenue Growth with a negative growth rate, indicating potential challenges. In terms of Gross Profit, it is at the top, showcasing strong profitability. However, its Return on Equity is at the bottom, suggesting lower returns for shareholders compared to peers. Overall, Central Garden &amp; Pet's performance is mixed compared to its peers in the analysis.</p>
<h3>Delving into Central Garden &amp; Pet's Background</h3>
<p>Central Garden &amp; Pet Co understands that home is central to life and has nurtured happy and healthy homes for over forty years. The segments of the company are the pet segment and garden segment. The company's trusted products are dedicated to helping lawns grow greener, gardens bloom bigger, pets live healthier and communities grow stronger. Central is home to a portfolio of more than sixty-five brands including Pennington, Nylabone, Kaytee, Amdro, and Aqueon, manufacturing and distribution capabilities, and a passionate, entrepreneurial growth culture. Central Garden and Pet is based in Walnut Creek, California, and has offices across North America and Europe.</p>
<h3>Central Garden &amp; Pet: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Challenges:</strong> Central Garden &amp; Pet's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately <strong>-2.63%</strong>. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Staples sector.</p>
<p><strong>Net Margin:</strong> Central Garden &amp; Pet's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>8.0%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Central Garden &amp; Pet's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>5.14%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Central Garden &amp; Pet's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>2.23%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Central Garden &amp; Pet's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.87</strong>.</p>
<p><a href="https://www.benzinga.com/quote/CENT/earnings"><strong>To track all earnings releases for Central Garden &amp; Pet visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


CENT

Insights into Central Garden & Pet's Upcoming Earnings

<p>Throughout the last three months, 24 analysts have evaluated Roblox (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">10</td>
<td align="right">12</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">7</td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Roblox, revealing an average target of $56.83, a high estimate of $65.00, and a low estimate of $49.00. Marking an increase of 15.98%, the current average surpasses the previous average price target of $49.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732287624_0_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>The standing of Roblox among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Marok</td>
<td>Raymond James</td>
<td>Maintains</td>
<td>Strong Buy</td>
<td>$60.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Jason Bazinet</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$63.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Benjamin Black</td>
<td>Deutsche Bank</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Matthew Cost</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$58.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Ross Sandler</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$50.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Eric Sheridan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$55.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Brian Pitz</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$62.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Aaron Lee</td>
<td>Macquarie</td>
<td>Raises</td>
<td>Outperform</td>
<td>$58.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Mike Hickey</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Cory Carpenter</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$62.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Jason Tilchen</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Clark Lampen</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$56.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Bernie McTernan</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Andrew Marok</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Strong Buy</td>
<td>$60.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Nick McKay</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$49.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Nick McKay</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$49.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Cory Carpenter</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$51.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Ken Gawrelski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$54.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Nick McKay</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$49.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Thomas Champion</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$54.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Jason Bazinet</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$53.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Clark Lampen</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$51.00</td>
<td>$47.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Roblox. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Roblox compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Roblox's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Roblox's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/RBLX/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Roblox analyst ratings.</strong></a></p>
<h2>Discovering Roblox: A Closer Look</h2>
<p>Roblox operates an online video game platform with 80 million daily active users that lets young gamers create, develop, and monetize games (or "experiences") for other players. The firm offers its developers a hybrid of a game engine, publishing platform, online hosting and services, marketplace with payment processing, and social network. The platform is a closed garden that Roblox controls, earning $3.5 billion in bookings in 2023 through in-game purchases and advertising while benefiting from outsourced game development. Unlike traditional video game publishers, Roblox is more focused on the creation of new tools and monetization techniques for its developers than creating new games or franchises.</p>
<h3>Understanding the Numbers: Roblox's Finances</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Roblox's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>28.84%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Communication Services sector.</p>
<p><strong>Net Margin:</strong> Roblox's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-26.04%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Roblox's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-153.7%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Roblox's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-3.64%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Roblox's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>9.26</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


RBLX

Roblox Stock: A Deep Dive Into Analyst Perspectives (24 Ratings)

<p>In the dynamic and fiercely competitive business environment, conducting a thorough analysis of companies is crucial for investors and industry enthusiasts. In this article, we will perform an extensive industry comparison, evaluating <b>Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)</b> in relation to its major competitors in the Software industry. By closely examining crucial financial metrics, market position, and growth prospects, we aim to offer valuable insights for investors and shed light on company's performance within the industry.</p>
<h3>Microsoft Background</h3>
<p>Microsoft develops and licenses consumer and enterprise software. It is known for its Windows operating systems and Office productivity suite. The company is organized into three equally sized broad segments: productivity and business processes (legacy Microsoft Office, cloud-based Office 365, Exchange, SharePoint, Skype, LinkedIn, Dynamics), intelligence cloud (infrastructure- and platform-as-a-service offerings Azure, Windows Server OS, SQL Server), and more personal computing (Windows Client, Xbox, Bing search, display advertising, and Surface laptops, tablets, and desktops).</p>
<table>
<thead>
<tr>
<th><strong>Company</strong></th>
<th><strong>P/E</strong></th>
<th><strong>P/B</strong></th>
<th><strong>P/S</strong></th>
<th><strong>ROE</strong></th>
<th><strong>EBITDA (in billions)</strong></th>
<th><strong>Gross Profit (in billions)</strong></th>
<th><strong>Revenue Growth</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Microsoft Corp</td>
<td>34.09</td>
<td>10.67</td>
<td>12.13</td>
<td>8.87%</td>
<td>$38.23</td>
<td>$45.49</td>
<td>16.04%</td>
</tr>
<tr>
<td>Oracle Corp</td>
<td>49.60</td>
<td>49.30</td>
<td>10.12</td>
<td>30.01%</td>
<td>$5.44</td>
<td>$9.4</td>
<td>6.86%</td>
</tr>
<tr>
<td>ServiceNow Inc</td>
<td>163.09</td>
<td>23.25</td>
<td>20.78</td>
<td>4.81%</td>
<td>$0.67</td>
<td>$2.21</td>
<td>22.25%</td>
</tr>
<tr>
<td>Palo Alto Networks Inc</td>
<td>51.58</td>
<td>22.07</td>
<td>17.04</td>
<td>6.33%</td>
<td>$0.39</td>
<td>$1.62</td>
<td>-2.32%</td>
</tr>
<tr>
<td>CrowdStrike Holdings Inc</td>
<td>518.19</td>
<td>30.72</td>
<td>25.25</td>
<td>1.75%</td>
<td>$0.12</td>
<td>$0.73</td>
<td>31.74%</td>
</tr>
<tr>
<td>Fortinet Inc</td>
<td>47.25</td>
<td>79.35</td>
<td>12.70</td>
<td>90.26%</td>
<td>$0.66</td>
<td>$1.24</td>
<td>13.0%</td>
</tr>
<tr>
<td>Gen Digital Inc</td>
<td>30.11</td>
<td>8.76</td>
<td>4.88</td>
<td>7.92%</td>
<td>$0.51</td>
<td>$0.78</td>
<td>3.07%</td>
</tr>
<tr>
<td>Monday.Com Ltd</td>
<td>642.47</td>
<td>14.18</td>
<td>15.66</td>
<td>-1.28%</td>
<td>$-0.02</td>
<td>$0.23</td>
<td>32.67%</td>
</tr>
<tr>
<td>Dolby Laboratories Inc</td>
<td>29.83</td>
<td>3.09</td>
<td>6.13</td>
<td>2.39%</td>
<td>$0.07</td>
<td>$0.27</td>
<td>4.9%</td>
</tr>
<tr>
<td>CommVault Systems Inc</td>
<td>43.32</td>
<td>26.87</td>
<td>8.58</td>
<td>5.56%</td>
<td>$0.02</td>
<td>$0.19</td>
<td>16.06%</td>
</tr>
<tr>
<td>QXO Inc</td>
<td>29.19</td>
<td>1.50</td>
<td>26.60</td>
<td>-0.21%</td>
<td>$-0.03</td>
<td>$0.01</td>
<td>-2.0%</td>
</tr>
<tr>
<td>Qualys Inc</td>
<td>33.15</td>
<td>12.22</td>
<td>9.51</td>
<td>10.53%</td>
<td>$0.05</td>
<td>$0.13</td>
<td>8.36%</td>
</tr>
<tr>
<td>Progress Software Corp</td>
<td>36.95</td>
<td>6.93</td>
<td>4.26</td>
<td>6.88%</td>
<td>$0.06</td>
<td>$0.15</td>
<td>2.11%</td>
</tr>
<tr>
<td>Teradata Corp</td>
<td>35.73</td>
<td>23.25</td>
<td>1.67</td>
<td>32.0%</td>
<td>$0.08</td>
<td>$0.27</td>
<td>0.46%</td>
</tr>
<tr>
<td>SolarWinds Corp</td>
<td>59.32</td>
<td>1.63</td>
<td>2.85</td>
<td>0.94%</td>
<td>$0.07</td>
<td>$0.18</td>
<td>5.5%</td>
</tr>
<tr>
<td><strong>Average</strong></td>
<td><strong>126.41</strong></td>
<td><strong>21.65</strong></td>
<td><strong>11.86</strong></td>
<td><strong>14.13%</strong></td>
<td><strong>$0.58</strong></td>
<td><strong>$1.24</strong></td>
<td><strong>10.19%</strong></td>
</tr>
</tbody>
</table>
<style>
        table {
            width: 100%;
            border-collapse: collapse;
            font-family: Arial, sans-serif;
            font-size: 14px;
        }

        th, td {
            padding: 8px;
            text-align: left;
        }

        th {
            background-color: #293a5a;
            color: #fff;
            text-align: left;
        }

        tr:nth-child(even) {
            background-color: #f2f4f8;
        }

        tr:hover {
            background-color: #e1e4ea;
        }

        td:nth-child(3), td:nth-child(5) {
            text-align: left;
        }

        .dividend-amount {
            font-weight: bold;
            color: #0d6efd;
        }

        .dividend-frequency {
            font-size: 12px;
            color: #6c757d;
        }
    </style><p>Through a thorough examination of Microsoft, we can discern the following trends: </p>
<ul>
<li>
<p>A Price to Earnings ratio of <b>34.09</b> significantly below the industry average by <b>0.27x</b> suggests undervaluation. This can make the stock appealing for those seeking growth.</p>
</li>
<li>
<p>With a Price to Book ratio of <b>10.67</b>, significantly falling below the industry average by <b>0.49x</b>, it suggests undervaluation and the possibility of untapped growth prospects.</p>
</li>
<li>
<p>The stock's relatively high Price to Sales ratio of <b>12.13</b>, surpassing the industry average by <b>1.02x</b>, may indicate an aspect of overvaluation in terms of sales performance.</p>
</li>
<li>
<p>With a Return on Equity (ROE) of <b>8.87%</b> that is <b>5.26%</b> below the industry average, it appears that the company exhibits potential inefficiency in utilizing equity to generate profits.</p>
</li>
<li>
<p>Compared to its industry, the company has higher Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of <b>$38.23 Billion</b>, which is <b>65.91x</b> above the industry average, indicating stronger profitability and robust cash flow generation.</p>
</li>
<li>
<p>With higher gross profit of <b>$45.49 Billion</b>, which indicates <b>36.69x</b> above the industry average, the company demonstrates stronger profitability and higher earnings from its core operations.</p>
</li>
<li>
<p>The company is experiencing remarkable revenue growth, with a rate of <b>16.04%</b>, outperforming the industry average of <b>10.19%</b>.</p>
</li>
</ul>
<h3>Debt To Equity Ratio</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732287617_0.png" alt="debt to equity" /></p>
<p>The debt-to-equity (D/E) ratio assesses the extent to which a company relies on borrowed funds compared to its equity.</p>
<p>Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.</p>
<p>When examining Microsoft in comparison to its top 4 peers with respect to the Debt-to-Equity ratio, the following information becomes apparent:</p>
<ul>
<li>
<p>Microsoft exhibits a stronger financial position compared to its top 4 peers in the sector, as indicated by its lower debt-to-equity ratio of <b>0.21</b>.</p>
</li>
<li>
<p>This suggests that the company has a more favorable balance between debt and equity, which can be seen as a positive aspect for investors.</p>
</li>
</ul>
<h3>Key Takeaways</h3>
<p>For Microsoft in the Software industry, the PE and PB ratios are low compared to peers, indicating potential undervaluation. However, the high PS ratio suggests overvaluation based on revenue. The low ROE may indicate lower profitability compared to peers, despite high EBITDA and gross profit margins. The high revenue growth suggests strong performance in generating sales.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


MSFT

Performance Comparison: Microsoft And Competitors In Software Industry

<p>In the latest quarter, 8 analysts provided ratings for Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $74.88, a high estimate of $95.00, and a low estimate of $58.00. Witnessing a positive shift, the current average has risen by 20.13% from the previous average price target of $62.33.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1732287615_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The perception of Celestica by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Vogt</td>
<td>UBS</td>
<td>Announces</td>
<td>Neutral</td>
<td>$95.00</td>
<td>-</td>
</tr>
<tr>
<td>George Wang</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$91.00</td>
<td>-</td>
</tr>
<tr>
<td>Daniel Chan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Matthew Sheerin</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Paul Treiber</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$75.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Thanos Moschopoulos</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$72.00</td>
<td>$64.00</td>
</tr>
<tr>
<td>Daniel Chan</td>
<td>TD Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$68.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Matthew Sheerin</td>
<td>Stifel</td>
<td>Maintains</td>
<td>Buy</td>
<td>$58.00</td>
<td>$58.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Celestica. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Celestica compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Celestica's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Celestica's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CLS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Celestica analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Celestica</h2>
<p>Celestica Inc offers supply chain solutions. The company has two operating and reportable segments: Advanced Technology Solutions (ATS) and Connectivity &amp; Cloud Solutions (CCS). The ATS segment consists of the ATS end market and is comprised of the Aerospace and Defense, Industrial, health tech, and Capital Equipment businesses. Its Capital Equipment business is comprised of the semiconductor, display, and robotics equipment businesses, and the CCS segment consists of Communications and Enterprise end markets, Enterprise end market is comprised of its servers and storage businesses. The company generates a majority of its revenue from the Connectivity &amp; Cloud Solutions segment.</p>
<h3>Celestica: A Financial Overview</h3>
<p><strong>Market Capitalization:</strong> Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.</p>
<p><strong>Revenue Growth:</strong> Celestica's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>22.33%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Celestica's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.67%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>5.06%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Celestica's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>1.55%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.52</strong>, Celestica adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Comments

Emmaus Life Sciences

Emmaus Life Sciences (EMMA) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga